These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31782938)

  • 1. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A subgroup cluster-based Bayesian adaptive design for precision medicine.
    Guo W; Ji Y; Catenacci DVT
    Biometrics; 2017 Jun; 73(2):367-377. PubMed ID: 27775814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian paradigm for decision-making in proof-of-concept trials.
    Pulkstenis E; Patra K; Zhang J
    J Biopharm Stat; 2017; 27(3):442-456. PubMed ID: 28166459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling.
    Zang Y; Guo B; Han Y; Cao S; Zhang C
    Stat Med; 2019 Jul; 38(15):2883-2896. PubMed ID: 30968435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.
    Götte H; Donica M; Mordenti G
    J Biopharm Stat; 2015; 25(5):1020-38. PubMed ID: 24914474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-to-event analysis with treatment arm selection at interim.
    Di Scala L; Glimm E
    Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
    Liu Y; Kairalla JA; Renfro LA
    Biometrics; 2022 Dec; 78(4):1441-1453. PubMed ID: 34415052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of the interim analysis in adaptive enrichment designs.
    Benner L; Kieser M
    J Biopharm Stat; 2018; 28(4):622-632. PubMed ID: 29064745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian adaptive design with biomarkers for targeted therapies.
    Eickhoff JC; Kim K; Beach J; Kolesar JM; Gee JR
    Clin Trials; 2010 Oct; 7(5):546-56. PubMed ID: 20571131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
    Su L; Chen X; Zhang J; Gao J; Yan F
    Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
    Ondra T; Dmitrienko A; Friede T; Graf A; Miller F; Stallard N; Posch M
    J Biopharm Stat; 2016; 26(1):99-119. PubMed ID: 26378339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-finding approach for genomic patterns in phase I trials.
    Kaneko S; Hirakawa A; Kakurai Y; Hamada C
    J Biopharm Stat; 2020 Sep; 30(5):834-853. PubMed ID: 32310707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.